No Yes Ok

Archive

« Older Entries Newer Entries »

LSP's portfolio company Syntaxin sold to Ipsen Monday, July 15th, 2013
LSP, the specialist European healthcare investor, is proud to announce today the successful sale of its portfolio company Syntaxin (UK) to Ipsen (F). A PDF version of Syntaxin’s press release can be found here. Under t [...]
Amphivena, a Subsidiary of Affimed AG, Completes $14 Million Equity Financing and Signs Agreement with Janssen Monday, July 15th, 2013
Heidelberg, Germany, July 15th, 2013: Affimed Therapeutics AG, the therapeutic TandAb antibody company, announced today that its subsidiary Amphivena Therapeutics Inc., a drug discovery company developing bispecific Tand [...]
Hybrigenics first half 2013 revenues: robust 12% growth Thursday, July 11th, 2013
Paris, 11 July 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases and specialised [...]
Curetis Initiates Prospective Multicenter Unyvero™ Study in Europe Tuesday, July 9th, 2013
- Study to demonstrate added value of Unyvero™ P50 pneumonia application in clinical routine - Holzgerlingen, Germany, July 9, 2013 -- Curetis AG today announced the start of an additional prospective, multicenter c [...]
LSP's portfolio company Kreatech sold to Leica Monday, July 8th, 2013
It is with great pleasure that LSP – the specialist European healthcare investment firm – announces the successful sale of its portfolio company Kreatech Diagnostics (NL) to Leica Biosystems (UK). A Pdf version of Le [...]
LSP’s portfolio company Prosensa successfully listed on the Nasdaq Wednesday, July 3rd, 2013
It is with great pleasure that today, LSP – the specialist European healthcare investment firm – announces that its portfolio company Prosensa was successfully listed on the Nasdaq stock exchange on Friday June 28th [...]
Hybrigenics acquires Dualsystems Biotech’s yeast two-hybrid (Y2H) activities Monday, July 1st, 2013
Hybrigenics Services will significantly strengthen its worldwide leadership as the reference Y2H service provider to screen functional protein interactions Paris, 01 July 2013 – Hybrigenics (ALHYG), a bio-pharmaceut [...]
Prosensa holding B.V. prices initial public offering Monday, July 1st, 2013
Leiden, the Netherlands—June 27, 2013—Prosensa Holding B.V. (“Prosensa”) announced today the pricing of its initial public offering of 6,000,000 of its ordinary shares at an initial public offering price of $1 [...]
Lyxumia® is first diabetes therapy of its class approved in Japan for use in combination with basal insulin Friday, June 28th, 2013
- First once-daily prandial GLP-1 receptor agonist offering a new treatment option for Japanese people living with type 2 diabetes Paris, France - June 28, 2013 - Sanofi (EURONEXT : SAN and NYSE : SNY) announced toda [...]
Merus Presents Preclinical Data on its Novel Bispecific Antibody MCLA-117 at EHA 2013 Monday, June 17th, 2013
- Clinical Candidate Designed for the Treatment of Acute Myeloid Leukemia (AML) - Utrecht, The Netherlands, June 17, 2013 – Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

LSP's portfolio company Syntaxin sold to Ipsen Monday, July 15th, 2013
LSP, the specialist European healthcare investor, is proud to announce today the successful sale of its portfolio company Syntaxin (UK) to Ipsen (F). A PDF version of Syntaxin’s press release can be found here. Under t [...]
Amphivena, a Subsidiary of Affimed AG, Completes $14 Million Equity Financing and Signs Agreement with Janssen Monday, July 15th, 2013
Heidelberg, Germany, July 15th, 2013: Affimed Therapeutics AG, the therapeutic TandAb antibody company, announced today that its subsidiary Amphivena Therapeutics Inc., a drug discovery company developing bispecific Tand [...]
Hybrigenics first half 2013 revenues: robust 12% growth Thursday, July 11th, 2013
Paris, 11 July 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases and specialised [...]
Curetis Initiates Prospective Multicenter Unyvero™ Study in Europe Tuesday, July 9th, 2013
- Study to demonstrate added value of Unyvero™ P50 pneumonia application in clinical routine - Holzgerlingen, Germany, July 9, 2013 -- Curetis AG today announced the start of an additional prospective, multicenter c [...]
LSP's portfolio company Kreatech sold to Leica Monday, July 8th, 2013
It is with great pleasure that LSP – the specialist European healthcare investment firm – announces the successful sale of its portfolio company Kreatech Diagnostics (NL) to Leica Biosystems (UK). A Pdf version of Le [...]
LSP’s portfolio company Prosensa successfully listed on the Nasdaq Wednesday, July 3rd, 2013
It is with great pleasure that today, LSP – the specialist European healthcare investment firm – announces that its portfolio company Prosensa was successfully listed on the Nasdaq stock exchange on Friday June 28th [...]
Hybrigenics acquires Dualsystems Biotech’s yeast two-hybrid (Y2H) activities Monday, July 1st, 2013
Hybrigenics Services will significantly strengthen its worldwide leadership as the reference Y2H service provider to screen functional protein interactions Paris, 01 July 2013 – Hybrigenics (ALHYG), a bio-pharmaceut [...]
Prosensa holding B.V. prices initial public offering Monday, July 1st, 2013
Leiden, the Netherlands—June 27, 2013—Prosensa Holding B.V. (“Prosensa”) announced today the pricing of its initial public offering of 6,000,000 of its ordinary shares at an initial public offering price of $1 [...]
Lyxumia® is first diabetes therapy of its class approved in Japan for use in combination with basal insulin Friday, June 28th, 2013
- First once-daily prandial GLP-1 receptor agonist offering a new treatment option for Japanese people living with type 2 diabetes Paris, France - June 28, 2013 - Sanofi (EURONEXT : SAN and NYSE : SNY) announced toda [...]
Merus Presents Preclinical Data on its Novel Bispecific Antibody MCLA-117 at EHA 2013 Monday, June 17th, 2013
- Clinical Candidate Designed for the Treatment of Acute Myeloid Leukemia (AML) - Utrecht, The Netherlands, June 17, 2013 – Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund